Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14159619 | 0.95 | SMN1; SMN2 (0.43) | DPP4DPP7L3MBTL1HPGDHTT | |
| SCHEMBL13359380 | 0.91 | HPGD (0.41) | HPGDHTTMAPTLMNAALOX12 | |
| SCHEMBL15451847 | 0.85 | HTT (0.46) | HPGDHTTMAPTLMNAALOX12 | |
| SCHEMBL5661094 | 0.84 | MMP1 (0.42) | DPP4DPP7L3MBTL1HPGDHTT | |
| SCHEMBL5661089 | 0.84 | MMP1 (0.42) | DPP4DPP7L3MBTL1HPGDHTT | |
| SCHEMBL16906218 | 0.83 | CA2 (0.44) | DPP4HPGDHTTMAPTLMNA | |
| SCHEMBL15451943 | 0.83 | CYP1A2 (0.46) | HPGDMAPTALDH1A1KDM4E | |
| SCHEMBL13359381 | 0.81 | ALDH1A1 (0.51) | L3MBTL1HPGDHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2385406 | 0.81 | HPGD (0.40) | DPP4DPP7L3MBTL1HPGDHTT | |
| SCHEMBL3548621 | 0.81 | HPGD (0.36) | HPGDHTTMAPTLMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718283-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-04-16 | — | — | EP | claimed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | claimed |
| US-20110130286-A1 | Piperazine Compounds with Herbicidal Effect | BASF SE (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7714131-B2 | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070072858-A1 | Process for the stereoselective preparation of (-)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072858-A1 | Process for the stereoselective preparation of (-)-halofenate and derivatives thereof | CCNY, C1S, CBR3 | DPP4 952/4885DPP7 4034/4885L3MBTL1 2860/4885 |
| US-20110130286-A1 | Piperazine Compounds with Herbicidal Effect | CAT, DDT, CIP2A | DPP4 329/4885DPP7 192/4885L3MBTL1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.